Palleon Pharma competitors

J Scott Wolchko are a President/CEO/COO at FATE THERAPEUTICS INC and Board Member at FATE THERAPEUTICS INC. They have worked as Chief Financial Officer at Bocada and VP:Operations/CFO at FATE THERAPEUTICS INC. J studied at University of Virginia and Alpha Omega Alpha Medical Honor Society.

Experienced Board Member, Inventor and Serial Entrepreneur with a demonstrated history of success in the biotechnology industry. Skilled in Biotechnology, Product Development, Life Sciences and Transactions. Strong business development professional with a Ph.D. focused in Pharmaceutical Sciences from the University of Nottingham. Winner EY Entrepreneur of the Year 2014, NJ Region.

Dr. McCamish has significant leadership in the life science industry, most recently serving as President and Chief Executive Officer of Forty Seven Inc., which he led through IPO and multiple financings until the acquisition by Gilead for approximately $4.9 Billion. Dr. McCamish has also served as the Global Head of Biopharmaceutical Development of Novartis' Sandoz division, receiving Novartis's Chairman award each year from 2010-2015. Prior to his time at Novartis, Dr. McCamish was a Vice President and Chief Medical Officer at several companies including PDL BioPharma, Perlegen Sciences, and Facet Labs, which was acquired by Abbott Laboratories due in part to Dr. McCamish's work advancing multiple myeloma and multiple sclerosis therapies. Additionally, Dr. McCamish has also held senior research and development roles at Amgen Inc. and Abbott Laboratories. Dr. McCamish received his PhD in Human Nutrition from Penn State University and his MD from the University of California, Los Angeles (UCLA). He completed his residency and fellowship training at the University of California, Davis (UC Davis). Dr. McCamish has been named one of the top 50 global antibody industry influencers by the European Antibody Congress and has held professorships at UC Davis and The Ohio State University.

Robert Ross is a Board Member at Obsidian Therapeutics, Board Member at SURFACE ONCOLOGY INC., and Chief Executive Officer at SURFACE ONCOLOGY INC. and is based in Brookline, Massachusetts. He has worked as Chief Medical Officer at SURFACE ONCOLOGY INC.. Robert studied at Columbia University in the City of New York between 1995 and 1999, Teachers College Columbia University, and Harvard University between 2005 and 2007.